Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Background

To explore the possibility of a combination of dabrafenib and SHP2 inhibitor in the treatment of anaplastic thyroid carcinoma and to provide a new therapeutic strategy for the treatment of anaplastic thyroid cancer.

Methods

Firstly, a drug resistance model was established, and the expression levels of related RTK were detected by qPCR. Western blot was used to detect the protein expression levels of Akt and MAPK signaling pathways in the control group, single-drug group and two-drug combination group. The gene silencing of SHP2 was achieved by transfection of siRNA and verified by Western blot. CCK8 kit and clone formation assay were used to detect cell proliferation activity. model of mutant thyroid cancer cells was established by subcutaneous injection of mice and then divided into four groups. Tumor diameter was measured every two days. Immunohistochemistry was used to evaluate the expression of p-ERK, p-AKT and Ki67 in mouse tumors.

Results

In this study, dabrafenib-resistant ATC cells were first constructed, and the response of RTKs in drug-resistant cells was upregulated to activate Akt and MER/ERK pathways. The activation of Akt and MEK/ERK pathways in the combination group was significantly inhibited, and the proliferation ability of tumor cells was significantly reduced compared with Dabrafenib, SHP099 group and DMSO group. To verify that SHP099 was not off-target, we also silenced SHP2 expression by transfection with siRNA and obtained the same results. Finally, by building a mouse drug resistance model, we confirmed that dabrafenib and SHP099 can also play a powerful anti-cancer effect .

Conclusion

The SHP2 inhibitor SHP099 can effectively reverse the drug resistance of dabrafenib through inhibiting the reactivated RAS signaling pathway in anaplastic thyroid cancer. The combination of dabrafenib with SHP2 inhibitor has shown significant tumor suppressive effects for dabrafenib-resistant cells and it may be a new therapeutic strategy with longer lasting therapeutic benefits.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520623666230214093122
2025-08-08
2026-03-02

  • From This Site

    /content/journals/acamc/10.2174/1871520623666230214093122
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WiltshireJ. DrakeT. UttleyL. BalasubramanianS. Systematic review of trends in the incidence rates of thyroid cancer.Thyroid2016261115411552
     [Google Scholar]
  2. CoelhoM. RaposoL. GoodfellowB.J. AtzoriL. JonesJ. ManadasB. The potential of metabolomics in the diagnosis of thyroid cancer.Int. J. Mol. Sci.202021155272
     [Google Scholar]
  3. NikitskiA. RominskiS. CondelloV. KayaC. WankhedeM. PanebiancoF. YangH. AltschulerD. NikiforovY.E. Mouse model of thyroid cancer progression and dedifferentiation driven by STRN-ALK expression and loss of p53: Evidence for the existence of two types of poorly differentiated carcinoma.Thyroid2019291014251437
     [Google Scholar]
  4. SainiS. MakerA. BurmanK. PrabhakarB.S. Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.Biochim. Biophys. Acta Rev. Cancer201918722188262
     [Google Scholar]
  5. MolinaroE. RomeiC. BiaginiA. SabiniE. AgateL. MazzeoS. MaterazziG. Sellari-FranceschiniS. RibechiniA. TorregrossaL. BasoloF. VittiP. EliseiR. Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies.Nat. Rev. Endocrinol.20171311644660
     [Google Scholar]
  6. CapdevilaJ. WirthL. ErnstT. Ponce AixS. LinC. RamlauR. ButlerM. DelordJ. GelderblomH. AsciertoP. FasoloA. FührerD. Hütter-KrönkeM. FordeP. WronaA. SantoroA. SadowP. SzpakowskiS. WuH. BostelG. FarisJ. CameronS. VargaA. TaylorM. PD-1 blockade in anaplastic thyroid carcinoma.J. Clin. Oncol.2020382326202627
     [Google Scholar]
  7. KillockD. Targeted therapies: Precision medicine for ATC - BRAF and MEK inhibition shows promise.Nat. Rev. Clin. Oncol.20171412712713
     [Google Scholar]
  8. ZamanA. WuW. BivonaT.J.C. Targeting oncogenic BRAF: Past, present, and future.Cancers20191181197
     [Google Scholar]
  9. NikiforovY. NikiforovaM. Molecular genetics and diagnosis of thyroid cancer.Nat. Rev. Endocrinol.2011710569580
     [Google Scholar]
  10. XingM. HaugenB.R. SchlumbergerM. Progress in molecular-based management of differentiated thyroid cancer.Lancet2013381987110581069
     [Google Scholar]
  11. PuszkielA. NoéG. BellesoeurA. KramkimelN. PaludettoM.N. Thomas-SchoemannA. VidalM. GoldwasserF. ChatelutE. BlanchetB. Clinical pharmacokinetics and pharmacodynamics of dabrafenib.Clin. Pharmacokinet.2019584451467
     [Google Scholar]
  12. ProiettiI. SkrozaN. MicheliniS. MambrinA. BalduzziV. BernardiniN. MarchesielloA. TolinoE. VolpeS. MaddalenaP. Di FraiaM. ManginoG. RomeoG. PotenzaC. BRAF inhibitors: Molecular targeting and immunomodulatory actions.Cancers20201271823
     [Google Scholar]
  13. MenziesA.M. LongG.V. MuraliR. Dabrafenib and its potential for the treatment of metastatic melanoma.Drug Des. Devel. Ther.20126391405
     [Google Scholar]
  14. CorcoranR.B. EbiH. TurkeA.B. CoffeeE.M. NishinoM. CogdillA.P. BrownR.D. Della PelleP. Dias-SantagataD. HungK.E. FlahertyK.T. PirisA. WargoJ.A. SettlemanJ. Mino-KenudsonM. EngelmanJ.A. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.Cancer Discov.201223227235
     [Google Scholar]
  15. HopkinsB.D. PauliC. DuX. WangD.G. LiX. WuD. AmadiumeS.C. GoncalvesM.D. HodakoskiC. LundquistM.R. BarejaR. MaY. HarrisE.M. SbonerA. BeltranH. RubinM.A. MukherjeeS. CantleyL.C. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.Nature20185607719499503
     [Google Scholar]
  16. JinL. ChunJ. PanC. LiD. LinR. AlesiG.N. WangX. KangH.B. SongL. WangD. ZhangG. FanJ. BoggonT.J. ZhouL. KowalskiJ. QuC.K. SteuerC.E. ChenG.Z. SabaN.F. BoiseL.H. OwonikokoT.K. KhuriF.R. MaglioccaK.R. ShinD.M. LonialS. KangS. MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation.Cancer Cell2018342315330.e317
     [Google Scholar]
  17. HerrR. HalbachS. HeizmannM. BuschH. BoerriesM. BrummerT. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.Oncogene2018371215761593
     [Google Scholar]
  18. RyanM.B. Fece de la CruzF. PhatS. MyersD.T. WongE. ShahzadeH.A. HongC.B. CorcoranR.B. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition.Clin. Cancer Res.202026716331643
     [Google Scholar]
  19. SmithM.P. WellbrockC. Molecular pathways: Maintaining MAPK inhibitor sensitivity by targeting nonmutational tolerance.Clin. Cancer Res.2016222459665970
     [Google Scholar]
  20. GrossmannK.S. RosárioM. BirchmeierC. BirchmeierW. The tyrosine phosphatase Shp2 in development and cancer.Adv. Cancer Res.20101065389
     [Google Scholar]
  21. ZhiJ. YiJ. HouX. WangW. YangW. HuL. HuangJ. GuoS. RuanX. GaoM. ZhengX. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.Am. J. Cancer Res.2022121247264
     [Google Scholar]
  22. LiY. YuanY. ZhangF. GuoA. CaoF. SongM. FuY. XuX. ShenH. ZhengS. PanY. ChangW. Therapeutic suppression of FAK-AKT signaling overcomes resistance to SHP2 inhibition in colorectal carcinoma.Front. Pharmacol.202112739501
     [Google Scholar]
  23. HeynenG. LisekK. VogelR. Wulf-GoldenbergA. AlcanizJ. MontaudonE. MarangoniE. BirchmeierW. Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.Breast Cancer Res.202224123
     [Google Scholar]
  24. LuH. LiuC. HuynhH. LeT.B.U. LaMarcheM.J. MohseniM. EngelmanJ.A. HammermanP.S. CaponigroG. HaoH.X. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.Oncotarget2020113265281
     [Google Scholar]
  25. TangK. JiaY.N. YuB. LiuH.M. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.Eur. J. Med. Chem.2020204112657
     [Google Scholar]
  26. WangJ.R. ZafereoM.E. DaduR. FerrarottoR. BusaidyN.L. LuC. AhmedS. Gule-MonroeM.K. WilliamsM.D. SturgisE.M. GoepfertR.P. GrossN.D. LaiS.Y. GunnG.B. PhanJ. RosenthalD.I. FullerC.D. MorrisonW.H. IyerP. CabanillasM.E. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma.Thyroid201929810361043
     [Google Scholar]
  27. KarouliaZ. GavathiotisE. PoulikakosP.I. New perspectives for targeting RAF kinase in human cancer.Nat. Rev. Cancer20171711676691
     [Google Scholar]
  28. WangJ. PollardK. AllenA.N. TomarT. PijnenburgD. YaoZ. RodriguezF.J. PratilasC.A. Combined inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors.Cancer Res.2020802353675379
     [Google Scholar]
  29. SongZ. WangM. GeY. ChenX.P. XuZ. SunY. XiongX.F. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.Acta Pharm. Sin. B20211111329
     [Google Scholar]
  30. LeungC.O.N. TongM. ChungK.P.S. ZhouL. CheN. TangK.H. DingJ. LauE.Y.T. NgI.O.L. MaS. LeeT.K.W. Overriding adaptive resistance to sorafenib through combination therapy with Src homology 2 domain-containing phosphatase 2 blockade in hepatocellular carcinoma.Hepatol.2020721155168
     [Google Scholar]
  31. DardaeiL. WangH.Q. SinghM. FordjourP. ShawK.X. YodaS. KerrG. YuK. LiangJ. CaoY. ChenY. LawrenceM.S. LangenbucherA. GainorJ.F. FribouletL. Dagogo-JackI. MyersD.T. LabrotE. RuddyD. ParksM. LeeD. DiCeccaR.H. MoodyS. HaoH. MohseniM. LaMarcheM. WilliamsJ. HoffmasterK. CaponigroG. ShawA.T. HataA.N. BenesC.H. LiF. EngelmanJ.A. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.Nat. Med.2018244512517
     [Google Scholar]
/content/journals/acamc/10.2174/1871520623666230214093122
Loading
Targeting SHP2 Reverses BRAF Inhibitor Tolerance in Anaplastic Thyroid Carcinoma
Anti-Cancer Agents in Medicinal Chemistry 26, 70 (2026); https://doi.org/10.2174/1871520623666230214093122
/content/journals/acamc/10.2174/1871520623666230214093122
/content/journals/acamc/10.2174/1871520623666230214093122
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): BRAF inhibitor; combination; SHP099; therapeutic strategy; thyroid cancer; tolerance

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test